Shield Therapeutics (STU:1JS) Revenue: €42.72 Mil (TTM As of Dec. 2025)

What is Shield Therapeutics Revenue?

Shield Therapeutics STU:1JS Revenue is €42.72 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Shield Therapeutics's revenue for the six months ended in Dec. 2025 was €24.13 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was €42.72 Mil. Shield Therapeutics's Revenue per Share for the six months ended in Dec. 2025 was €0.02. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.04.

Warning Sign:

Shield Therapeutics PLC revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Shield Therapeutics was 6.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was 22.60% per year. During the past 5 years, the average Revenue per Share Growth Rate was -1.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 12 years, Shield Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 143.80% per year. The lowest was -56.80% per year. And the median was 26.00% per year.

Shield Therapeutics (STU:1JS) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Shield Therapeutics Revenue Related Terms

Shield Therapeutics Revenue Historical Data

* Premium members only.

The historical data trend for Shield Therapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics Revenue Chart

Shield Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Revenue

Get a 7-Day Free Trial

1.81

5.19

12.00

30.73

42.45

Shield Therapeutics Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
Revenue	Get a 7-Day Free Trial															8.57	11.27	19.15	18.60	24.13

STU:1JS vs ZTS, UTHR, VTRS: Revenue Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Shield Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Shield Therapeutics Revenue vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shield Therapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Shield Therapeutics's Revenue falls into.

Save Embed

Shield Therapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €42.72 Mil.

Frequently Asked Questions Learn more about Revenue →

What does a Revenue of €42.72 Mil mean?

Shield Therapeutics (STU:1JS) has a Revenue of €42.72 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Shield Therapeutics and its competitors.

Is Shield Therapeutics' Revenue too high?

Shield Therapeutics' current Revenue is €42.72 Mil.

How does Shield Therapeutics' Revenue compare to ZTS and UTHR?

Shield Therapeutics' Revenue of €42.72 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Revenue for a Drug Manufacturers company?

A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Revenue mean?

A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Shield Therapeutics and its competitors. Shield Therapeutics's current Revenue is €42.72 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Shield Therapeutics stock overvalued right now?

Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 32% below its estimated fair value. The current Revenue is €42.72 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Revenue calculated?

Revenue is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current Revenue is €42.72 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shield Therapeutics Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies LSE:EAH LSE:PXS LSE:MDH LSE:ANCR XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR HKSE:03692 VTRS NSE:DIVISLAB OSTO:SOBI NBIX NSE:TORNTPHARM

Other Exchanges SHIEF:USA STX:UK 1JS:Germany

Address Gateshead Quays, Northern Design Centre, Baltic Business Quarter, Newcastle, GBR, NE8 3DF

Website https://www.shieldtherapeutics.com

Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.